Scientific advisory board

ns.jpg

VADIM BICHKO (PhD, Chief Scientific Officer)

EDUCATION:
1986, PhD in molecular biology, Latvia University, Riga, Latvia.

PROFESSIONAL EXPERIENCE:
Dr. Bichko is a virologist with 15 years of successful research and development management experience in pharmaceutical and biotechnology companies. Prior to joining Viriom, he was Director of Research at Idenix Pharmaceuticals, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral infectious diseases, including hepatitis C, B, and HIV. Prior to that, he was a leading virology researcher at Scriptgen (Anadys) Pharmaceuticals and previously held various academic positions at Fox Chase Cancer Center in Philadelphia, Max Planck Institute for Biochemistry in Munich, Germany, and the Institute of Organic Synthesis in Riga, Latvia. Dr. Bichko is the author of numerous publications and patents in molecular virology. Under his leaderhip, several antiviral drug candidates (HCV, HIV) were advanced to the clinic.

men8.jpg

ROBERT L. MURPHY (MD, PROFESSOR, DIRECTOR OF THE CENTER FOR GLOBAL HEALTH AT NORTHWESTERN UNIVERSITY)

EDUCATION:
Professor Murphy has been with Northwestern University since 1978. After receiving his AB from Boston University, he attended the Loyola Stritch School of Medicine and later completed his internship, residency, and fellowship in infectious diseases at the McGaw Medical Center, Northwestern University, becoming a professor of medicine in 1999. He presently holds the distinguished post of John P. Phair Professor of Medicine.

PROFESSIONAL EXPERIENCE:
Dr. Robert L. Murphy is the Director of the Center for Global Health at Northwestern University (Illinois, USA). He also holds an appointment as Professeur Associé de Recherche at the Pierre et Marie Curie Université-Paris in France. Dr. Murphy’s primary research and clinical interest is in viral infections. His research includes drug development of new antiretroviral drugs and vaccines for HIV and viral hepatitis and the scale-up of therapy for AIDS, tuberculosis and malaria in sub-Saharan Africa.
Dr. Murphy is Special Advisor to the President’s Emergency Plan for AIDS Relief (PEPFAR) program in Nigeria, sponsored by the Harvard School of Public Health, where he has overseen the opening of 42 clinics that currently treat over 75,000 patients with HIV/AIDS. He also consults on NIH-supported antiretroviral education projects in Senegal. Dr. Murphy's international activities and interests include assisting in the establishment of an AIDS Clinic in rural southern Kenya funded by the African Village Clinics Foundation of Chicago.

Dr. Murphy is the Principal Investigator for the National Institutes for Allergy and Infectious Diseases (NIAID) Adult AIDS Clinical Trials Group (ACTG) at Northwestern. Within ACTG he has held numerous leadership positions including membership on the Scientific Agenda Steering Committee and Adult Executive Committee, the governing body of the group. He is a member of multiple medical societies and boards of several non-profit organizations including the Drucker Family Charitable Trust, the International AIDS Education Project, Objectif Recherche Vaccin SIDA and the Midwest AIDS Foundation, of which he is the founder.

men9.jpg

KLAUS KLAMPP (PHDPROFESSOR)

EDUCATION:
Dr. Klumpp holds a diploma degree in biology from the Technical University Darmstadt, Germany, and a PhD in virology. He has worked at Wellcome Research Laboratories, Beckenham, Kent, U.K., at the European Molecular Biology Laboratories (EMBL), Heidelberg, Germany, and at the EMBL in Grenoble, France. 

PROFESSIONAL EXPERIENCE:
2013 - present, Vice President of Discovery Research at Novira Therapeutics, Inc. 
Prior to joining Novira, Dr. Klumpp led research and development activities in the field of viral diseases for more than 15 years at Roche Palo Alto LLC, most recently as Vice President, Head of HCV Clinical Virology & Viral Biochemistry. Prior to Roche, he worked as a research assistant at GlaxoWellcome Research and Development (Stevenage, UK).

Dr. Klumpp worked extensively in R&D collaborations with external partner companies and academic laboratories. He was responsible for the discovery and transition into clinical development of a number of new leads and drug candidates for treatment of acute and chronic viral diseases, including influenza, hepatitis C, HBV, Dengue and HIV. In addition, he supported the clinical development of antiviral drugs such as Tamiflu for the treatment and prophylaxis of influenza virus infection and Balapiravir, Mericitabine and Danoprevir, new antiviral agents for treatment of HCV infection. Dr. Klumpp serves as a Member of Scientific Advisory Board at Savira Pharmaceuticals GmbH and Vice President of discovery and development at Novira Therapeutics Inc.

JANET HAMMOND (PHDMD)

EDUCATION:
Dr. Hammond received her MD and PhD from the University of Cape Town, South Africa. 

PROFESSIONAL EXPERIENCE:
2011 - present, Senior VP and Global Head of Infectious Diseases at F. Hoffmann-La Roche managing early clinical development strategy and implementation. 
Dr. Hammond began her career in 1997 as a Clinical Program Head of Clinical Discovery in Virology at GlaxoSmithKline (GSK), where she oversaw founding and development of a new department and its medical strategy, IND submissions, and clinical development of small molecules and vaccines. Subsequently she led the Early Clinical research team at Bristol-Myers Squibb responsible for HIV Early Development and Virology Life Cycle management from 2002 to 2007. Dr. Hammond also served as CMO - Medical Affairs at Valeant from 2007 to 2011, where she was responsible for clinical and pharmacovigilance activities around the globe.

Dr. Hammond has been an exceptionally active contributor to infectious disease therapies, leading the submission of three New Drug Applications (NDA) and Marketing Authorization Applications, more than ten supplemental NDAs, and more than ten Investigational New Drug (IND) applications in the past thirteen years.

pornchai.png

Dr. Pornchai Matangkasombut (PHD,MD)

EDUCATION:
Dr. Matangkasombut received his BA, MD and PhD from University of Wisconsin.

PROFESSIONAL EXPERIENCE:

2006 - Present, Independent Director, Thai Beverage Public Company Limited. Prof. Pornchai Matangkasombut served as the President of the Mahidol University until 1999. From 1986 to 1990 he served as a Member of the Executive Board of the International Union of Microbiological Societies. He has been an Independent Director of Thai Beverage Public Company Limited since March 27, 2006.

Dr. Matangkasombut has been a Member of the International Union of Immunological Societies since 1971. He received the award of Chulachomklao Order (Special Third Class) from His Majesty the King of Thailand and the award of Palmes Academiques (Commandeur) from the Government of the Republic of France, the Borden Research Award in Medicine. Prof. Matangkasombut is also a Honorary Research Associate at Harvard University and a Visiting Professor at the Osaka University and the University of Saigon. 

men9.jpg

Milos petrovic (MD)

EDUCATION:
Milos Petrovic is a qualified doctor, he graduated from the Medical Department of Belgrade University, Serbia.

PROFESSIONAL EXPERIENCE:

1992, Dr. Petrovic started his career in pharmaceutical business in
the American company ICN Pharmaceuticals (“Valeant” at present) in Yugoslavia and then he had been working in the USA office of the company for 2 years.
1998 – 2000, Medical Director of Central and Eastern Europe in the Moscow office of ICN Pharmaceuticals.
2000 – 2002, Business Unit Manager of Pharmaceutical Division of F. Hoffmann - La Roche in Russia.
2002 – 2005, Regional Manager of Roche office in Macedonia, where he successfully built a team of professionals, who in 3 years managed to turn Roche into the leading Western pharmaceutical company in Macedonia.
2005 - 2014, General Manager of Roche in Moscow & Head of F. Hoffmann - La Roche in Russia and CIS.